Skip to main content

Bristol Myers Squibb Opdivo Qvantig revenue

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.9B

Opdivo Qvantig revenue at Bristol Myers Squibb came to $334.0M for the quarter to 30 Sep 2026, up 398.5% from a year earlier.

As Bristol Myers Squibb reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$0Mar 2024$0Jun 2024$0Sep 2024$0Dec 2024$9.0MMar 2025$30.0MJun 2025$67.0MSep 2025$163.0MMar 2026$261.0MJun 2026$334.0MSep 2026
Bristol Myers Squibb Opdivo Qvantig revenue, every reported period
Period endingOpdivo Qvantig revenueChange on a yearFiled
30 Sep 2026$334.0Mup 398.5%29 Oct 2026
30 Jun 2026$261.0Mup 770.0%30 Jul 2026
31 Mar 2026$163.0Mup 1711.1%30 Apr 2026
30 Sep 2025$67.0M—30 Oct 2025
30 Jun 2025$30.0M—31 Jul 2025
31 Mar 2025$9.0M—24 Apr 2025
31 Dec 2024$0—12 Feb 2025
30 Sep 2024$0—31 Oct 2024
30 Jun 2024$0—26 Jul 2024
31 Mar 2024$0—25 Apr 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Bristol Myers Squibb: International revenues · Gross product sales · Net product sales · Growth Portfolio revenue · Legacy Portfolio revenue · Eliquis revenue · Opdivo revenue · Orencia revenue · Yervoy revenue · Reblozyl revenue · Breyanzi revenue · Alliance and other revenues · Camzyos revenue · Opdualag revenue · Revlimid revenue · Zeposia revenue · Pomalyst/Imnovid revenue · Abecma revenue · Sotyktu revenue · Alliance revenues · Sprycel revenue · Abraxane revenue · Krazati revenue · Cobenfy revenue · financial statements

Every KPI and segment of BMY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.